← All indications
Brugada Syndrome
An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.
Drugs by status
Phase 4 trials (3)
Phase 3 trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (20)
- Sanofi
- International Registry of Asymptomatic Brugada Syndrome
- University of Bordeaux
- Tel Aviv University
- University of Western Brittany
- University of Strasbourg
- François Rabelais University
- University of Toulouse
- University of Montpellier
- University of Lille
- University of Lyon
- University of Nantes
- University of Paris
- University of Poitiers
- Aix-University of Marseille
- University of Rennes
- University of Antwerp
- University of Grenoble
- University of Picardie Jules Verne
- University of Lorraine
Organization Involved with Phase 2 Indications (1)
Organization Involved with Other Experimental Indications (1)